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 Fuel cell draws increasing attention because of its high theoretical efficiency (over 90%). 
However, the actual efficiency is limited by the large overpotential (500-600 mV) of the oxygen 
reduction reaction (ORR), which demands a potent ORR catalyst to decrease the overpotential. 
Towards this goal, my thesis focuses on mimicking the heme-copper oxidase and engineering a 
multi-copper oxidase for efficient oxygen reduction with high turnover frequency and low 
overpotential 
Heme-copper oxidases catalyze four-electron reduction of oxygen to water, and the 
energy harvested is utilized to drive the synthesis of adenosine triphosphate. While much effort 
has been made to design a catalyst mimicking the function of terminal oxidases, most 
biomimetic catalysts have much lower activity than native oxidases. Herein we report a designed 
oxidase in myoglobin with an O2 reduction rate (52 s
−1) comparable to that of a native 
cytochrome (cyt) cbb3 oxidase (50 s
−1) under identical conditions. We achieved this goal by 
engineering more favorable electrostatic interactions between a functional oxidase model 
designed in sperm whale myoglobin and its native redox partner, cyt b5, resulting in a 400-fold 
electron transfer (ET) rate enhancement. Achieving high activity equivalent to that of native 
enzymes in a designed metalloenzyme offers deeper insight into the roles of tunable processes 
such as ET in oxidase activity and enzymatic function and may extend into applications such as 
more efficient oxygen reduction reaction catalysts for biofuel cells. 
iii 
 
The other system we studied is a multi-copper oxidase called small laccase (SLAC), 
which consists of a catalytic trinuclear copper center (TNC) and a Type 1 (T1) Cu center for 
electron transfer. However, the ORR overpotential of SLAC is relatively high (400 mV) because 
of the lower reduction potential (Eo') of the T1 Cu (370 mV) compared to fungal laccases (780 
mV). Built upon our previous success in tuning reduction potentials of T1 Cu protein azurin, we 
have made significant progress in tuning the T1 Cu center in SLAC to decrease its over-
potentials. We achieved the goal by structural overlays of the T1 Cu domain of SLAC and the 
high potential azurin reported by Lu group to search for mutations that can potentially increase 
the Eo' of T1 Cu through non-covalent secondary sphere interactions such as dipole interactions 
and hydrophobicity and validated the hypothesis that the Eo' of T1 Cu plays a crucial role in 
defining the onset potential of ORR. The results provide a viable approach to decrease the ORR 
overpotential for biofuel cell application.  
Additionally, we studied the role of the axial methionine in tuning the onset potential of 
small laccase. We observed a positive correlation between the onset potential of oxygen 
reduction and the A// hyperfine of the T1 copper. The hyperfine coupling originates from the 
coupling between Cu nuclei and electron spin and a greater hyperfine coupling indicates a larger 
spin density localized on the Cu center, i.e., the Cu is more electron deficient resulting in a 
higher reduction potential. 
In summary, we achieved the oxidase activity equivalent to that of native heme-copper 
oxidase in a designed metalloenzyme and attained a 180 mV overpotential with a rationally 
design triple mutant of small laccase. This work demonstrated the redox tuning of a multi-copper 
oxidase by non-covalent interactions and provided a viable approach to decrease the ORR 
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CHAPTER 1: INTRODUCTION 
Portions of this chapter are previously published and are here reproduced with permission from 
Dioxygen-dependent Heme Enzymes, Edited by Masao Ikeda-Saito and Emma Raven, 2018. 
FUEL CELL AND OXYGEN REDUCTION CATALYST 
Fuel cell is an electrochemical device that generates electricity by the oxidation of the 
fuel at the anode and the reduction of the oxidant at the cathode, in which the cathode reaction is 
typically oxygen reduction.1 Unlike a thermal engine, the energy efficiency is not restricted by 
the Carnot cycle and can theoretically reach over 90%, making it a promising source of 
alternative energy. However, the actual energy efficiency of a fuel cell is below 50% because of 
the overpotentials from both the anode and cathode. For instance, the anode overpotential of a 
hydrogen fuel cell is typically around 50 mV whereas the cathode overpotential is 500-600 mV 
which is the major contributor to the overpotential.1 To improve the energy efficiency of the fuel 
cell, i.e., to reduce the overpotential, there is a practical demand for an efficient oxygen reduction 
catalyst. 
The oxygen reduction reaction a four-electron four-proton reaction that involves the 
cleavage of an O=O double bond with a bond energy of 498 kJ mol-1. Additionally, the activation 
of the strong O=O bond is a multi-electron multi-proton process that makes the reaction 
kinetically sluggish. If the overall reaction proceeds through a stepwise mechanism, the reaction 
requires a significant overpotential as shown in the Pourbaix diagram (Figure 1.1).2 Considering 
a stepwise one electron reduction and single protonation of Ox to form RedH (at pH 7), the 




Figure 1.1. Overpotential requirements resulting from high-energy catalytic 
intermediates. (A) The Pourbaix diagram for a PCET reaction denotes the most stable 
species at each potential and pH. (B) Frost (oxidation state) diagram showing the redox 
reactions during oxygen reduction. Reprinted from Ref. 2. 
additional amount of energy denoted overpotential. In oxygen reduction reaction, if the proton 
and electron transfer events are not fully concerted, the formation of superoxide radical and other 
3 
 
reactive oxygen species correspond to high energy Red intermediates in the model described 
above and gives rise to the overpotential.2 An ideal oxygen reduction catalyst would fully 
synchronize the four-electron four-proton transfer events and facilitate the reaction to proceed 
through a concerted mechanism bypassing any reduction intermediates. 
To decrease the activation energy of the O=O bond cleavage, several types of oxygen 
reduction catalysts have been reported including metal or alloy nanomaterials,3,4 bioinspired 
small molecules such as metal porphyrins5,6 and biomimetic copper complexes7–9 and protein-
based catalysts.9–13 The small molecule and solid-state catalysts have been discussed in several 
comprehensive review papers.14–18 Herein we will focus on two families of oxygen reducing 
enzymes in nature. Native oxidases, such as multi-copper oxidases and heme-copper oxidases, 
couple the reduction of oxygen to water with a variety of biological transformations, including 
the essential aerobic respiration catalyzed heme-copper oxidase, the degradation of recalcitrant 
lignin mediated by fungal laccase,19,20 biomineralization catalyzed by bacterial manganese 
oxidase21 and iron metabolism mediated by ceruloplasmin.22,23 The oxygen reduction reaction 
was harnessed as either energy source to power the proton translocation as in the case of heme-
copper oxidase24 or utilized as a terminal oxidant in biology. 
MULTI-COPPER OXIDASES FOR ELECTROCATALYSIS 
Multi-copper oxidase (MCO) catalyzes the four-electron reduction of oxygen to water 
and oxidizes a variety of substrates including small organic molecules, metal ions and biomass 
such as lignin. The active site of MCO consists of a mononuclear center for electron transfer and 
a trinuclear cooper center (TNC) for oxygen binding and activation (Figure 1.2). Based on the 
spectroscopic features, the copper centers are classified as Type 1 (T1), Type2 (T2) and Type 3 
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(T3) copper centers.25 Most fungal and plant MCOs consist of three cupredoxin domains whereas 
those from human or bacterial sources are homotrimers in which each monomer contains two 
cupredoxin domains and the TNC resides at the domain interface between two monomers. 
 
Based on the reduction potential of the T1 Cu center, MCOs are classified into high 
potential MCOs such as fungal laccases which exhibit an reduction potential of 600-800 mV, 
medium potential MCOs from plants with 500-600 mV and low potential laccases from bacterial 
with under 500 mV reduction potential.26 The high potential fungal laccase has drawn significant 
attention because it is able to harness nearly the entire oxidation power of oxygen to oxidize 
organic molecules with high reduction potentials, i.e., the overpotential of oxygen reduction can 
be as low as 100 mV.13 
Figure 1.2. The crystal structure of Steptomyces coelicolor laccase and the structure of the 
active sites. (PDB: 3CG8.) 
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Armstrong and coworked covalently modified the pyrolytic edge graphite electrode with 
a monolayer of anthracene via diazonium coupling and utilized the anthracene as a substrate 
analog to recognize hydrophobic pocket near the T1 Cu center of Trametes vesicolor laccase. 
The laccase modified electrode exhibits efficient oxygen reduction activity with a remarkable 
<140 mV overpotential at pH 4.11 Furthermore, Gewirth and coworkers modified the gold 
electrode surface with anthracene-2-methanethiol and backfilled with inert ethylthiol and 
observed a catalytic current with only 100 mV overpotential. The catalytic current exhibits a 
linear Tafel behavior with a 144 mV/dec slope (Figure 1.3), which confirms the direct one 
electron transfer from the electrode to the T1 Cu center.13 
The high onset potential of fungal laccase makes it a promising biocatalyst for oxygen 
reduction reaction, however, the large molecular weight and thus molecular footprint on the 
Figure 1.3. The immobilization of Tv laccase on Au-Anthracene electrode and the Tafel plot of 
oxygen reduction reaction. Reprinted from Ref. 13. 
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electrode. Additionally, the optimized pH range of most fungal laccases including Trametes 
vesicolor laccase is around pH 427 which poses a higher probability of electrode corrosion and 
limits performance of such enzyme electrodes under physiological condition. Furthermore, these 
fungal laccases need the critical posttranslational modification such as glycosylation to perform 
any enzymatic activity, however, bacterial expression systems lack the glycosylation machinery 
to facilitate the necessary post-translational modification and thus limits the possibility of 
obtaining these enzymes by recombinant expression.  
An alternative catalyst could be streptomyces coelicolor laccase, also called small 
laccase,28 which is a bacterial laccase that can be overexpressed from Escherichia coli and thus 
amendable to genetic modifications by site directed mutagenesis. Compare to the three-domain 
fungal laccases, this bacterial laccase contains only two domains, one domain houses the T1 Cu 
for electron transfer and the trinuclear copper center resides at the interface between two 
different domains. The two-domain laccase is one of the smallest multi-copper oxidase and 
Figure 1.4. Immobilization of small laccase on the multi-wall carbon nanotube electrodes via 
click chemistry between the Cyclooctyne layer and genetically encoded p-azidophenylalanine. 
Reprinted from Ref. 28. 
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therefore named small laccase. The small molecular footprint allows a higher theoretical density 
of catalysts on the electrode surface. Moreover, small laccase is catalytically active over a much 
wider pH range from pH 4 to 9.28  
Despite of the advantages of small laccase, a critical barrier is the low reduction potential 
as compared to the fungal laccases. Chen, Liu and coworkers genetically incorporated 
azidophenylalanine onto the surface of small laccase to enable the covalent linkage of the 
enzyme to the multi-wall carbon nanotube electrode by click chemistry (Figure 1.4).29 The 
reduction potential of small laccase is around 400 mV compared to trametes vesicolor laccase 
which has a reduction potential of 780 mV. The proposed mechanism (Figure 1.5) 30 of multi-
Figure 1.5. The reaction mechanism of small laccase. Reprinted from Ref. 30. 
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copper oxidase indicates that the fully reduced state can bind oxygen and form a transient peroxy 
intermediate which rapidly decays into a highly oxidative native intermediate. The native 
intermediate accepts electrons from the substrate and return to the fully reduced state to initiate 
another catalytic cycle. A unique feature of the small laccase is the active site Tyr108 adjacent to 
the trinculear copper center30,31 that presumably protects the native intermediate from quenching 
by adventitious oxidation of the protein scaffold.  
The reaction mechanism described above indicates that reaction starts with oxygen 
binding to the fully reduced enzyme. In order to initiate the oxygen reduction reaction, the native 
intermediate needs to accept electrons from the electrode to regenerate the fully reduced enzyme. 
In multi-copper oxidases, the T1 Cu is the first entry site for the incoming electrons, therefore, 
the first electron transfer to the T1 Cu is the prerequisite for the oxygen reduction reaction. In the 
Figure 1.6. Tuning the reduction potential of azurin by tuning the hydrophobicity of the 
axial ligand and the no-covalent interactions in the secondary coordination sphere. 
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case of electrocatalysis, the electron donor is not a small molecule but the electrode. During the 
electrocatalysis, the minimal reducing power required to inject the first electron into the T1 Cu 
center will determine the onset potential of the reaction. Our working hypothesis is that the 
reduction potential of the T1 Cu center determines the minimal reducing potential required to 
inject the electrons to the T1 Cu center to supply the oxygen reduction, i.e., increasing the onset 
potential of the T1 Cu is a strategy to increase the onset potential of oxygen reduction.  
TUNING THE REDUCTION POTENTIAL OF CUPREDOXIN 
Cupredoxins in nature covers a 600 mV range of reduction potential with the same greek 
key barrel scaffold and the two histidine and one cysteine in the primary coordination sphere.32 
Lu and coworkers have tuned the reduction potential of azurin over a range of 700 mV by tuning 
the hydrophobicity of the axial Met12133,34 and the hydrophobicity and hydrogen-bonding in the 
secondary coordination sphere which surpasses the highest and lowest end of native range.35,36 
Figure 1.7. Tuning the reduction potential of cupredoxin by modulating the 
dipole interactions and hydrogen bonding interactions. Reprinted from Ref. 37. 
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Specifically, F114P, N47S, and F114N mutants modulate the hydrogen bonding to the 
Cu-S(Cys) bond, as well as protein-derived dipoles near this interaction, ultimately leading to 
modulation of Eº. Mutating Phe114 to proline eliminates the backbone imide which originally 
serves as a hydrogen bonding donor to Cys112, which results in a more electron rich cysteine 
ligand that favors the Cu(I) state and thus increases the reduction potential. The side chain 
carbonyl of Asn47 imposes a negatively orientated dipole moment towards the cysteine ligand 
that decreases the reduction potential of azurin, which is removed in the N47S mutation. On the 
contrary, F114N mutation inserts a negative dipole within 5A of the Cu center and thus increases 
the reduction potential (Figure 1.7).35,37 Further desolvation of the active site by M44F and 
G116F mutations increase the reduction potential up to 970 mV achieving the high end of the 
Figure 1.8. By mutating only five residues and using two metal ions (Cu and Ni) in a single 
protein, Az, the entire range of physiological potential can be covered. Reprinted from Ref. 36. 
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physiological reduction potential range. Replacing the Cu with Ni achieved -1 V which exceeds 
the lowest end in the biological range (Figure 1.8).36  
Computational investigation in the experimental results suggests that the changes in the 
reduction potentials of the mutants originate from both covalent, for examples in the case of 
M121X and F114P mutants, and nonlocal electrostatic component such as the dipole 
interactions.37 These two components can be experimentally deconvoluted by directly estimating 
the covalent component by X-ray absorption spectroscopy. These factors can have similar order 
of impact of the reduction potential individually and can exert either additive or contradictory 
effects depending on the location distant and direction of the dipoles. However, the local 
conformational dynamics of the protein scaffold may be able to compensate the effects of the 
mutants by minute geometrical change within the vicinity of the mutation site and thus partially 
diminish the designed effect. 
FUNCTIONAL MODELS OF HEME-COPPER OXIDASE 
Heme-copper oxidase (HCO) is the last enzyme in the respiratory chain that catalyzes the 
complete four-electron reduction of dioxygen to water without releasing any detectable reactive 
oxygen species (ROS).38–41 Heme-copper oxidases form the class of terminal oxidases that 
accounts for over 90% of dioxygen conversion.42 The energy harvested from oxygen reduction is 
utilized for transmembrane proton pumping that drives the synthesis of ATP.42  
Structure of heme-copper oxidases 
Heme-copper oxidases are membrane proteins composed of multiple domains and 
possessing numerous metal cofactors.41 The active site of HCO contains a heme center and a 
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copper ion chelated by three histidine residues in the distal pocket, denoted CuB. A conserved 
histidine-tyrosine crosslink at the active site is involved in the proton-coupled electron transfer 
(PCET) during oxygen reduction. The HCO active site receives electrons from cytochrome c (cyt 
c) through a dinuclear CuA domain and a mediating heme a. Despites years of effort and 
progress, the mechanism of HCO has not been fully elucidated because of the practical difficulty 
involved in isolating membrane proteins and the overlapping spectroscopic features of the 
multiple metal cofactors in HCO.43 A complimentary approach to study the mechanism of HCO 
is to design a structural and functional model in either a small molecule44–47 or protein scaffold43 
to mimic the key features of the native enzyme. Synthetic models of HCO were successfully 
designed by Collman45,46 and Karlin,44 on which there are multiple excellent reviews 
elsewhere.5,6,44,48–50 More recently, Lu and coworkers designed biosynthetic models of HCO 
using myoglobin (Mb) as a scaffold and systematically studied the role of critical chemical 
processes required for oxidase activity, such as electron51,52 and proton transfer.53–56 
Functional model of heme-copper center in Mb scaffold  
Sperm whale Mb is a small (17 kDa), soluble single heme protein with M oxygen 
binding affinity that has been thoroughly characterized, making it an ideal scaffold to engineer a 
biosynthetic model of HCO.43,52 To mimic the CuB center in HCO, two histidine mutations, 
L29H and F43H, were incorporated to serve as the ligands for CuB together with the native distal 
H64.57,58 The resultant CuBMb exhibited oxygen reduction activity forming hydrogen peroxide. 
Further design focused on the HCO active site Y244, which is critical for PCET during oxygen 
reduction. Based on the sequence and structural homology with native HCO, a Tyr residue was 
incorporated at two positions, F33Y and G65Y, which improved water production to 75% as 
measured by an oxygen electrode in the presence of catalase and superoxide dismutase.43  
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Fine tuning oxidase activity with non-native heme cofactors 
The biosynthetic model of HCO in Mb scaffold not only provided a functional model but 
also facilitated mechanistic study to understand the critical structural features for promoting 
oxygen reduction activity, such as the heme cofactor, the nonheme metal ion, the active site Tyr, 
and an extended hydrogen bonding network, by systematically tuning a specific factor within the 
same protein scaffold.  
The E°’ of heme among different HCO has been found to vary by over 500 mV,59–61 
which presumably correlates with measured oxidase activity. Lu and coworkers systematically 
evaluated the effect to heme E°’ on oxidase activity by reconstituting apoMb with a series of 
non-native heme cofactors exhibiting progressively higher E°’ (Figure 1.9).51 A positive 
correlation was observed between the oxidase activity and the E°’ of the heme cofactors (Figure 
1.9). Further rapid kinetics study revealed that a 210 mV increase in E°’ enhanced the 
Figure 1.9. (A) Protein scaffold of F33Y-CuBMb. (B) Heme b cofactor present in F33Y-
CuBMb. (C) Heme a present in the catalytic site of bovine HCO. (D) Diacetyl heme (E) 
Monofomyl heme and (F) Diformyl heme incorporated in F33Y-CuBMb apo-protein. (G) 
Variation of O2 reduction activity with heme E° for F33Y-CuBMb variants. Dotted blue line 
indicates E°’ of WT Mb and bovine HCO. 
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intermolecular electron transfer rate between the reductant and the active site by 30-fold, but 
oxygen binding affinity decreased by three-fold, which overall accounted for the observed 10-
fold increase in the oxidase activity.62 
The role of nonheme metal in promoting O-O bond cleavage  
 Heme-copper oxidases employ a heme-copper center for the four-electron oxygen 
reduction whereas nitric oxide reductase (NOR), another member of the HCO superfamily, 
utilizes iron as the nonheme metal ion to catalyze the two-electron reduction of nitric oxide to 
nitrous oxide.24,63 Despite years of study, it remained unclear why copper was selected for 
oxidase activity while iron was selected for NOR activity, largely because of the technical 
difficulty in substituting the nonheme metal ions in native HCO while retaining the integrity and 
functionality of the enzymes. Using the mutant V68E-CuBMb, denoted FeBMb, Lu and 
coworkers incorporated iron, copper, or zinc selectively into the nonheme metal site (Figure 
1.10) and observed 10- and 30-fold enhancement of oxidase activity with Fe- and Cu- bound at 
the nonheme metal site compared to the Zn-bound form (Figure 1.10).64 The most recent study 
showed that MnII and CoII bound to the nonheme metal site can also confer oxidase activity.65 
Protein film voltammetry and X-ray absorption spectroscopy demonstrated that the nonheme Cu 
and Fe are involved in donating electrons to the O-O bond to facilitate bond cleavage. 
Computational studies suggest that the higher E°’ and greater electron density in the d orbitals of 
Cu enhance weakening of the O–O bond and result in higher oxidase activity than Fe.64 
Non-covalent interactions in tuning the reduction potential and proton transfer  
The biosynthetic model of HCO in Mb provides not only a heme center to promote 
oxygen reduction, but also a protein scaffold supporting multiple non-covalent interactions that 
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modulate the proton and electron transfer processes. Besides replacing the heme cofactors, the 
E°’ of the biosynthetic model can also be modulated by non-covalent interactions. For instance, 
the S92A mutation removes hydrogen bonding interactions from the heme proximal ligand H93 
and from the heme propionate which together increase the heme E°’ by 40 mV.51  
The active site Tyr in native HCO has been shown by both top-down and bottom-up 
design approaches to be critical to oxidase activity. Crystallographic studies revealed an 
extended hydrogen bonding network in F33Y-CuBMb mutant that is absent in WT Mb, 
connecting the coordinating water and the hydroxyl group on Tyr33 through two water 
molecules. Furthermore, cryoreduction electron paramagnetic resonance (EPR) spectroscopy 
Figure 1.10. (A-C) The crystal structure of the FeBMb mutant (I107E-FeBMb) shows the 
catalytic haem–non-haem heterobinuclear metal centre with non-haem metal ions bound. (D) 
The UV–vis spectroscopic measurements of the FeBMb(Fe
II) variants display changes in the 
Soret (420–445 nm) and visible (500–700 nm) regions on incorporation of non-haem FeII and 
CuI metal ions. (E) The rates of O2 reduction to form either H2O (blue) or ROS (red). 
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demonstrated that the ferric-peroxo intermediate, resulting from the one-electron reduction of the 
oxy-ferrous complex, can convert to ferric hydroperoxo in F33Y-CuBMb by accepting one 
proton upon annealing whereas the ferric-peroxo species persists in WT Mb (Figure 1.11). The 
combined crystallographic and spectroscopic evidence (Figure 1.11) confirmed the presence of a 
hydrogen bonding network that assists O-O bond cleavage by proton delivery.56 Moreover, rapid 
freeze quench EPR suggested the formation of a tyrosyl radical during oxygen reduction.66  
Defining the role of the active site tyrosine by genetic incorporation of tyrosine analogs 
The biosynthetic model F33Y-CuBMb provides an elegant system for spectroscopic and 
kinetic study related to the active site Tyr. To gain further insights into the roles of E°’ and pKa 
of the active site Tyr in oxygen reduction, those two factors were systematically varied by 
genetic incorporation of a series of unnatural amino acid Tyr analogs. Assays for oxidase activity 
indicated a clear negative correlation between both the oxygen reduction rate and percent water 
production with increasing pKa of the hydroxyl group on F33Y (Figure 1.12). The oxidase 
activity also correlates with the E°’ of the Tyr analogs at F33Y.54,55 A closer mimic of native 
Figure 1.11. (Left) EPR spectra of oxy-WTMb and oxy-F33Y CuBMb after cryoreduction. 
(Middle) formation and trapping of (hydro)peroxo intermediates by cryoreduction. (Right) 
Crystal structure of oxy-F33Y-CuBMb determined at 1.27 Å resolution (PDB: 5HAV), 
compared with that of oxy-WTMb. 
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HCO was made by incorporating an imidazole-tyrosine by codon expansion to replicate the 
conserved His-Tyr crosslink.53 The resultant Phe33imiTyr variant exhibited an eight-fold 
increase in selectivity towards water formation and a three-fold increase in oxygen reduction 
rate, demonstrating that the His-Tyr crosslink plays a role in both catalytic efficiency and 
specificity in HCO. 
 Besides gaining mechanistic insight, the biosynthetic model of HCO also has potential to 
act as the cathode catalyst in biofuel cells. Dey, Lu, and coworkers covalently attached the heme 
cofactor in G65Y-CuBMb on a modified Au electrode by an azide-alkyne click reaction and 
observed a turnover frequency of 5000 s-1 for electrocatalytic oxygen reduction. In situ Raman 
spectroscopy suggested that the direct electron transfer from the electrode bypasses the 
dissociation of the heme-coordinated hydroxyl group, which is the rate limiting step in the 
solution phase reaction, resulting in the observed rapid catalytic turnover.67 
 
 
Figure 1.12. (Left) Crystal structure of the F33Y/L29H/F43H sperm whale myoglobin 
(F33Y-CuBMb) (Right) The correlation between the activity of F33Y-CuBMb and pKa of Tyr 
and Tyr analogs.  
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Oxygen activation by de novo designed heme proteins  
Beyond re-engineering native heme proteins to impart novel functions, much progress 
has been made in de novo design of minimal scaffolds to accommodate cofactors such as flavin 
and heme.68 Moser, Dutton, and coworkers reported the de novo design of tetrahelical bundles 
for heme binding,69,70 which exhibit a variety of functions including O2 binding,
71 O2 reduction 
producing ROS,68 and electron transfer.68 
De novo designed heme-binding maquettes 
Dutton and coworkers initially designed a 27-amino acid helical peptide with a flexible 
Cys-Gly-Gly-Gly tether, mimicking the heme b binding helices B and D of the cytochrome bc1 
complex. Two 31-amino acid peptides form a homotetramer through disulfide bonds within a 
dihelical unit and non-covalent interactions between two units, bearing two His ligands on each 
peptide for heme b binding with µM binding affinity.69 Spectroelectrochemical studies showed 
distinct midpoint potentials at the two non-equivalent heme sites and a cooperative effect in the 
reduction of the four heme cofactors. It has been proposed that the electrostatic repulsion 
between the heme cofactors favors the reduction of one heme cofactor, i.e., elevates the midpoint 
potential by approximately 100 mV. The E°’ of the heme cofactors can be further modulated by 
secondary coordination sphere interactions.72  
Oxygen binding and activation by cytochrome c maquettes 
The heme binding maquettes mentioned above demonstrated the potential of protein 
design and engineering to create minimal structural motifs required to accommodate multiple 
functional cofactors such as heme. Beyond cofactor binding, Dutton, Moser, and coworkers also 
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designed a tetrahelical peptide that was expressed and purified directly from cells and which is 
capable of reversible oxygen binding.71 The design of this oxygen transport maquette was three-
fold: (1) initial design of a repetitive helix-forming sequence with histidine ligands inserted at the 
appropriate positions; (2) addition of a flexible linker to constrain the helices and exclude water 
access to prevent autoxidation; and (3) tuning the orientation of E11, E18, and E25 to weaken the 
heme-histidine ligation and increase oxygen affinity, similar to neuroglobin. The designed 
peptide exhibited an oxygen affinity of 32 nM and a 10-fold discrimination in favor of oxygen 
binding over carbon monoxide binding. 
A limitation of symmetrical, homodimeric helical bundles is that the repetitive peptides 
cannot bind diverse cofactors in a single maquette. This limitation was overcome recently by 
Figure 1.13. Helical bundle topology and cofactor insertion. (a) The tethered dimer is 
converted to a single chain form by linking helices 2 and 3, allowing the sequence of all four of 
the helices to be different. (b) Diversity in function is accomplished by securing a variety of 
cofactors (top) to various sites (bottom) within the maquette using appropriate cofactor 
anchoring amino acids (green). 
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Dutton and coworkers, reporting a single peptide chain folding into a heterotetrahelical maquette 
(Figure 1.13).68 The helices are connected from N- to C- terminal by loops rather than a disulfide 
tether, enabling the anchoring of various cofactors at specific residues to impart diverse 
functions, such as intramolecular electron transfer, ligand binding and exchange, and ROS 
production (Figure 1.13). Replacing the disulfide tether with a flexible loop resulted in a helical 
monomer that retained oxygen affinity and furthermore enabled superoxide generation, 
analogous to GLB26 from C. elegans, which reduces oxygen to superoxide by rapid outer sphere 
electron transfer.  
Three mechanistically distinct designing principles led to this functional peptide: tuning 
the axial ligand exchange by rotational strain, permitting water access, and modulating the heme 
E°’. Specifically, replacing three Glu residues with Ala relieved helical strain to inhibit the 
dissociation of the axial His that is crucial to oxygen binding. Permitting water to access the 
heme site facilitates inner sphere electron transfer for oxygen reduction mediated by water, and 
the heme E°’ in the maquette was sufficiently low (-290 mV) to reduce oxygen to superoxide. 
The designed ferrous heme in the maquette is oxidized during superoxide production at a rate of 
0.15 s-1, comparable to GLB26.68 
Electrocatalytic oxygen reduction by mimochromes 
 A series of helix-heme-helix sandwich motifs for heme binding were designed by 
Lombardi, Pavone, and coworkers, denoted mimochromes, in parallel to the emergence of heme-
binding maquettes. The initial design was a nonapeptide covalently linked to the propionates on 
the heme cofactor by a Lys sidechain based on the F-helix in human hemoglobin. The His 
residue in the nonapeptide serves as the axial ligand to the heme iron. For the convenience of 
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synthesis, the C- and N- termini were neutralized with amine and acetyl groups, respectively, and 
the redox active or charged residues were replaced with inactive or neutral residues. The 
resulting heme-bound nonapeptide was denoted mimochrome I. Further efforts were made to 
enhance stability and impart catalytic activity, such as peroxidase activity, by introducing intra- 
and inter-helical interactions. Notably, mimochrome IV, containing a pentacoordinated heme 
iron ligated by a single His, exhibited oxygen reduction activity when adsorbed by hydrophobic 
interactions on a thiol-modified Au electrode (Figure 1.14).73 These examples of bottom-up 
designed hemoproteins opened the possibility of exploring monooxygenase activity in 
miniaturized heme proteins.  
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CHAPTER 2: A DESIGNED METALLOENZYME ACHIEVING THE CATALYTIC 
RATE OF A NATIVE OXIDASE 
Portions of this chapter are previously published and are here reproduced with permission from 
J. Am. Chem. Soc., 2015, 137 (36), pp 11570–11573 
INTRODUCTION 
Metalloenzymes have fascinated scientists and engineers for many years, because the 
enzymes normally exhibit much higher activities than small inorganic catalysts, even though the 
metalloenzymes use only a limited number of physiologically available metal ions or metal-
containing cofactors and perform the reactions under much milder conditions. Rationally design 
of metalloenzymes that mimic native enzymes allow elucidation of structural features and 
mechanisms responsible for the high activity and efficient use of earth-abundant metal cofactors 
and facilitate design of more robust and cost-effective catalysts for many applications.1-11 A key 
measure of the success of this endeavor is the activity of the designed enzymes in comparison 
with the native enzyme they model. While tremendous progress has been made in the field, most 
reported metalloenzymes designed empirically or computationally display activities that are far 
below those of native enzymes they try to mimic.  
A representative metalloenzyme system of interest is terminal oxidases, such as cyt cbb3 
oxidase in the respiration chain, in which the O2 is reduced to H2O in a four electron (4e
-) 
process, and the energy harvested from this reduction is converted into a proton gradient that 
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drives the synthesis of adenosine triphosphate, the universal source of energy for most biological 
process.12-15 In addition to their important role in bioenergetics, cyt oxidases are also of interests 
to biofuel cell research, because the oxidases are among the most efficient oxygen reduction 
reaction catalysts, with lowest over-potentials and using earth abundant metal ions such as iron 
and copper, unlike the best industrial oxygen reduction reaction (ORR) fuel cell catalysts, which 
require precious platinum.16 To understand the efficiency of this important class of 
metalloenzymes, many synthetic models have been made to mimic its structure and function, 
with particular focus on the heme-copper center that at the active site of most oxidases.17-19 
Despite years of efforts by many groups, the activities of the biomimetic compounds in 
homogenous solution are still far below those of native oxidases.20   
As an alternative approach to biomimetic studies of native enzymes using small organic 
molecules, we use small and stable proteins, such as myoglobin (Mb) as scaffolds to design 
structural features that mimic native enzymes. Thanks to recent advances in molecular biology 
and biochemistry, it is now much easier and faster to prepare Mb and its variants than those of 
native oxidases and even synthetic models. For example, we can routinely design, express and 
purify Mb variants in about a week, with a typical yields of ~100 mg/L or more of media to grow 
E. coli. Mb functions as an O2 storage protein in biology. To transform the Mb into an oxidase, 
we have introduced conserved structural elements of heme-copper oxidases, one Tyr and two His 
residues into the distal pocket of Mb. One such variant, L29H/F43H/G65Y Mb (called G65Y-
CuBMb) was able to reduce O2 to water, with catalytic oxygen reduction rate of 0.30 s
-1 and 
1,000 turnovers, using ascorbate as a reductant and TMPD as a redox mediator.21 
While the above results demonstrate that we can rationally design a functional enzyme 
with a high number of turnovers, the catalytic rate (0.30 s-1) is still far below that of native 
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enzymes (e.g., cyt cbb3 oxidase from Rhodobacter sphaeroides has O2 reduction rate of 52 s
-1).22 
Our preliminary investigations of the G65Y-CuBMb and similarly designed Mb model enzymes 
suggest that electron transfer (ET) into the catalytic center may be rate limiting. This finding is 
consistent with the studies of native cyt c oxidase23 and some synthetic models, which showed 
that the electron delivery into the active site might be a rate-limiting step.24-26 In searching for 
new redox partners of Mb to increase the ET rate and potentially catalytic activity, we were 
excited to learn the work by Hoffman and coworkers, who replaced three negatively charged 
amino acids (Asp44, Asp60 and Glu85) in myoglobin with three positively charged lysines to 
improve electrostatic interactions between the Mb and its redox partner, cyt b5, which is 
negatively charged.27-28  Such a D44K/D60K/E85K variant, called Mb(+6), enhanced the rate of 
ET from the triplet state of Zn-deuteroporphyrin-substituted Mb to ferric cyt b5 dramatically by 
>2 orders of magnitude (from 5.5x103 s-1 to ~ 1.0x106 s-1).28  
Inspired by the work of Hoffman and coworkers, we hypothesized that the charge 
reversal mutation would also promote electron transfer in the opposite direction, that is, from 




ferrous cyt b5 to oxidized Mb(+6). The accelerated electron transfer in turn has the potential to 
deliver electrons to Mb(+6) at a sufficiently fast rate to ensure a four-electron reduction of 
oxygen to water, preventing the release of partially reduced oxygen species. We incorporated the 
charge reversal mutations to G65Y-CuBMb mutants, the most potent oxidase from the previous 
design and performed oxidase assay. 
MATERIALS AND METHODS  
Gene construction  
The gene of the soluble part of bovine cyt b5 and gene of NADH-cyt b5 reductase were 
synthesized (GenScript, Nanjing, China) and subcloned to pET22b plasmid with C-terminal His-
tag.  
Protein expression and purification  
Plasmid with NADH-cyt b5 reductase gene was transformed into BL21(DE3) competent 
cells (NEB). Cultures of E. coli BL21(DE3) cells containing the plasmid to express NADH-cyt 
b5 reductase were grown in LB media for 8 h at 37 °C and used to inoculate 2 L of LB media 
containing 100 mg/mL ampicillin. The culture was incubated at 37 °C for 16 h with shaking at 
210 rpm. Protein expression was induced by addition of Isopropyl β-D-1-thiogalactopyranoside 
(IPTG, GoldBio Technology, St. Louis, MO) to a final concentration of 1 mM. After 4h, the cells 
were harvested by centrifugation at 9000 x g for 10min. The harvested cell paste was re-
suspended in a lysis buffer containing 50 mM NaH2PO4, 10 mM imidazole, pH 8.0, 300 mM 
NaCl (50 mL). The suspension was then lysed by sonication (Misonix Sonicator 4000, 0.5 inch 
diameter probe) for a work time of 6 min (6 sec. on, 10 sec. rest). The crude lysate was 
30 
 
centrifuged at 20,000 x g for 30 min. The supernatant was incubated with Ni-NTA resin (5 mL, 
QIAGEN) for 0.5 h. NiNTA resin was washed with lysis buffer (10 mL) and protein was eluted 
with an imidazole gradient. Fractions with the target protein were pooled together and loaded 
unto size-exclusion column with Sephacryl S-100 resin (GE Lifesciences) for further 
purification. The identity and purity of the purified protein was verified by ESI mass 
spectrometry (calculated: 31671, observed: 31682).  
Plasmid with cyt b5 gene was transformed into BL21(DE3) competent cells (NEB). 
Cultures of E. coli BL21(DE3) cells containing the plasmid to express cyt b5 were grown in LB 
media (50 mL) for 16 h at 37 °C and used to inoculate 2 L of LB media containing 100 mg/mL 
ampicillin. The culture was incubated at 37 °C for 8 h with shaking at 210 rpm. Protein 
expression was induced by addition of IPTG to a final concentration of 1 mM. After 16h, the 
cells were harvested by centrifugation at 9000 x g for 10min.cyt b5 was purified using ion 
exchange chromatography before final size-exclusion chromatography. Identity and purity of the 
purified protein was verified by ESI mass spectrometry (calculated: 12860, observed: 12862). S3  
Plasmids with various Mb genes were transformed into BL21(DE3) competent cells 
(NEB). Cultures of E. coli BL21(DE3) cells containing the plasmids to express Mb were grown 
in LB media (50 mL) for 16 h at 37 °C and used to inoculate 1 L of TB media (tryptone, 12 g, 
yeast extract, 24 g, glycerol 0.4 mL in 1 L H2O with 0.017 M KH2PO4, 0.072 M K2HPO4) 
containing 100 mg/mL ampicillin. The cells were grown at 37 °C for 8 h with shaking at 210 
rpm, following 16 h induction with 1 mM IPTG and were harvested by centrifugation at 9000 x g 
for 10min.  
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G65Y-CuBMb (+6) was purified based on a modified inclusion body protocol. The cell 
pellet was resuspended in 50 mL of lysis buffer (10 mM Tris-HCl, 1 mM EDTA, 0.1% Triton X-
100, and 1 mM of phenylmethylsulphonyl fluoride (PMSF), pH 8.0), and the cells were lysed by 
sonication. The crude lysate was centrifuged at 20,000 x g for 30 min. After centrifugation, the 
pellet was collected, resuspended and washed twice with H2O to remove Triton X-100 and the 
remaining nucleic acid. The pellet was then resuspended in 50 mL of 7M guanidine 
hydrochloride (GuHCl) and sonicated until complete solubilization. After denaturation, the 
protein was refolded in the presence of heme. A hemin-CN stock solution containing 25 mg KCN 
and 7.5 mg hemin in 5 mL H2O was added to 500 mL of cold H2O. The solution was allowed to 
stir for ~10 min. Then the protein/GuHCl solution was added dropwise to the hemin-CN solution 
and allowed to stir for ~1 h after the last addition. The solution was centrifuged at 9000 x g for 
30 min to remove precipitant. The red/orange supernatant (~500 mL) was then dialyzed against 
12 L of 20 mM Tris, pH 7.2 overnight. The protein solution was centrifuged at 9000 x g for 30 
min to remove precipitate. The supernatant was incubated with pre-equilibrated Sepharose CM 
resin for 10 min. The resin was filtered out by a coarse frit and washed with 20 mM Tris, pH 8.0 
(50 mL). Protein was eluted by 20 mM Tris, 200 mM KCl, pH 8.0 (50 mL). The protein was 
concentrated to 8 mL and exchanged to 100mM pH 7 potassium phosphate buffer by buffer 
exchange in a Centricon ultrafiltration device (Millipore). It is further purified by size-exclusion 
chromatography. The identity and purity of protein was verified by ESI-MS (G65Y-CuBMb(+6), 
calculated: 17476.4, observed: 17484.0).  
Electron transfer study by stopped-flow spectrometry  
Experiments were performed on an Applied Photophysics Ltd. (Leatherhead, U.K.) 
SX18.MV stopped-flow spectrometer equipped with a 256 element photodiode array detector at 
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room temperature. Two-syringe mixing was employed to mix equal volumes of ferrous cyt b5 in 
degassed buffer with myoglobin in airsaturated buffer, both in 5 mM potassium phosphate buffer 
pH 6. The instrument was prepared for anaerobic stopped-flow by rinsing its lines out with 15 
mM dithionite solution followed by purging with degassed reaction buffer 10 mL, and finally 
rinsed by reactant five times before data collection. Special glass outer syringes fit with Teflon 
stoppers into which an argon line was run maintained an oxygen free environment.  
Cyt b5 was degassed and transferred into glove bag and reduced with dithionite. 
Reductant dithionite was removed by GE G-25 Sephadex desalting column. Cyt b5 was adjusted 
to a final concentration of 5 μM, stored into air-tight syringe with needle sealed with rubber 
septum, transferred out of the glove bag and immediately mounted in to the apparatus. Mb 
mutant was adjusted to a final concentration of 0.5 μM with air-saturated buffer. All reported 
data sets originally consisted of 1000 spectra collected over 1 to 500 s using logarithmic 
sampling. The integration period and minimum sampling period were both 1 ms. 
O2 reduction and H2O2 production assay O2 reduction was measured by using an 
Oxygraph Clark-type oxygen electrode (Hansatech Instruments) at 25°C or 37°C in 5 mM 
potassium phosphate buffer, pH 6.0. All experiments were performed three times to obtain 
standard deviation. The electrode was calibrated against air-saturated buffer and O2-depleted 
buffer prior to use. Protein was exchanged to 5 mM potassium phosphate buffer, pH 6.0. The 
buffer was treated with Chelex beads overnight before use. The final concentrations of 
myoglobin, cyt b5 and NADH-cyt b5 reductase were adjusted to 50 nM, 5 μM and 80 nM based 
on Soret absorption of Mb and cyt b5, and absorption of FAD in NADH-cyt b5 reductase. The 
native enzyme was added at last to initiate the catalysis, following the reported procedure, 
because of the instability of the enzyme.  
33 
 
H2O2 product was probed by HPO-100 hydrogen peroxide sensor (World Precision 
Instrumentation) and detected by Apollo 1000 one-channel free radical analyzer (World Precision 
Instrumentation) at 37°C in 5 mM potassium phosphate buffer, pH 6.0. HPO-100 sensor 
polarized in reaction buffer for 2 h prior to use. 30% H2O2 aqueous solution (Sigma) 11 μL was 
diluted with H2O 989 μL to prepare a standard 100 mM stock solution. Calibration curve was 
taken from 0.1 to 100 μM H2O2 aqueous solution.  
Measurement of reduction potential by spectroelectrochemical method  
The reduction potentials of both mutants were measured in 100 mM potassium phosphate 
buffer at pH 7 as previously described. 
RESULTS AND DISCUSSION 
Construction, expression and purification of G65Y-CuBMb(+6) were carried out using a 
protocol reported previously.21 The mutations were confirmed by DNA sequencing, while the 
corresponding protein variant containing the mutations was corroborated by mass spectrometry 
(calculated MW: 17477; observed MW: 17476). The electronic absorption spectra in the 
ultraviolet and visible region (UV-vis) of G65Y-CuBMb(+6) in both ferric and ferrous forms are 
similar to those of G65Y-CuBMb (Figure 2, 3), suggesting that the mutations have minimal 




Figure 2.2. UV-is spectra of oxidized and reduced G65Y-CuBMb(+6). 
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 ferrous G65Y-CuBMb(+6)

























Figure 2.3. UV-is spectra of oxidized and reduced G65Y-CuBMb. 




































         (reduced by dithioite)
35 
 
To determine the oxidase activity measured by the rate of oxygen reduction, we used O2-
selective electrode commonly used in monitoring catalytic activity of native oxidases (22, 29). In 
the presence of 0.8 μM NADH-cyt b5 reductase, the physiological redox partner of cyt b5 (30, 31) 
and 5 μM of cyt b5, the concentration of O2 in 50 nM G65Y-CuBMb(+6) decreased rapidly 
(Figure 2.5), with the rate of the oxygen reduction being 52 s-1. In contrast, the G65Y-CuBMb 
without the D44K/D60K/E85K mutations exhibited a rate of 0.3 s-1 under the same condition. 
Furthermore, the protein without the G65Y mutation (CuBMb) also exhibited low O2 reduction 
rate 8.1 s-1), which is consistent with the importance of the role of G65Y mutation in oxidase 
activity21. The rate of 52 s-1 is similar to that of native cbb3 oxidase (50 s
-1) under the same 
condition.  
































 NADH-cyt b5 reductase
         (as purified)
 NADH-cyt b5 reductase
         (reduced by dithionite)
Figure 2.4. UV-is spectra of oxidized and reduced NADH-cyt b5 reductase. 
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To confirm the dramatic increase of the oxidase activity of G65Y-CuBMb(+6) is due to 
the enhanced ET, we first repeated the above experiment by systematically removing each 
component of enzymes involved in the O2 reduction. As shown in Figure 2.6, minimal O2 
reduction occurred in the absence of either NADH-cyt b5 reductase, cyt b5 or G65Y-CuBMb(+6), 
suggesting all three enzymes play key roles in the enzymatic activity.  More importantly, we 
directly measured the ET rate between 5 μM of reduced cyt b5 and 0.5 μM of either G65Y-
CuBMb or G65Y-CuBMb(+6), at the same concentrations at which the O2 reduction was 
measured in Figure 2.5, by monitoring the oxidation of cyt b5 by the two Mb variants using 
stopped-flow UV-vis spectrometry. The pseudo first order rate constant between cyt b5 and 
G65Y-CuBMb(+6) was determined as (1.2 ± 0.2) x 10
1 s-1, which is ~400 fold faster than that of 
G65Y-CuBMb (3.0 ± 0.5) x 10
-2 s-1. This ET rate enhancement is similar to the rate enhancement 
Figure 2.5. Oxidase activity of G65Y-CuBMb in comparison with that of native cyt cbb3 
oxidase and G65YCuBMb with the same concentration, under the optimized condition. 
Typical condition: NADH 2 mM, cyt b5 reductase 0.80 μM, cyt b5 5 μM, G65Y-CuBMb(+6) 





of O2 reduction, which strongly suggests that the enhanced ET rate is mainly responsible for the 
increased oxidase activity.  
 
Figure 2.6. O2 reduction rate of different combination of G65YCuBMb(+6), cyt b5, and 
NADH-cyt b5 reductase. The final concentrations of G65YCuBMb(+6), cyt b5 and NADH-
cyt b5 reductase were adjusted to 50 nM, 5 μM and 80 nM. O2 reduction was measured 
immediately after addition of 0.2 mM NADH. Only significant O2 reduction was observed 
with all components. 
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The reduction potentials of G65Y-CuBMb(+6) and G65Y-CuBMb were determined to be 
(115 ± 11) and (129 ± 5) mV by spectroelectrochemical methods (Figure 2.8). Since the 
reduction potentials of both mutants are similar, these results suggest that the major contributor 
to the increased ET rate is the enhanced electrostatic interaction between the negatively charged 
cyt b5 and positively charged G65Y CuBMb(+6), not due to difference of ET driving force. 
Figure 2.7. ET studies between cyt b5 and G65Y-CuBMb and G65Y-CuBMb(+6). (a) 
Representative stopped-flow UV-visible spectra of cyt b5 oxidation catalyzed by G65Y-
CuBMb(+6) and time trace at characteristic wavelength (inset). (b) Time trace of cyt b5 
oxidation represented by absorption at 556 nm, overlaid with global spectroscopic fitting 





To investigate whether the O2 reduction in the Mb variant is a 4e
- process, as in native 
oxidases, we measured H2O2 produced from the reaction using an amperometric H2O2 sensor. 
Under the same condition as in the O2 reduction experiment shown in Figure 2.5, the G65Y-
CuBMb(+6) generates peroxide at 3.5 s
-1 (Figure 2.9), or 7% of total O2 reduced, while the 
G65Y-CuBMb produced 22% of peroxide (Figure 2.10)
21.  
Figure 2.8. UV-vis spectra of G65Y-CuBMb(+6) and (b) G65Y-CuBMb under -0.39 V to 0.56 V 




Furthermore, since the NADH used in the O2 reduction experiment is a two-electron 
reductant, the ratio of the rate of NADH consumed in the reaction over that of the O2 reduced 
can be used to determine whether the O2 reduction is a 4e
- process, as demonstrated in other 
heme enzymes32. The NADH oxidation was monitored by absorption at 352 nm (see Figure 
2.9)32. The rate of the reaction is compared to that of O2 reduction using O2-selectvie electrode 
under the same condition as in Figure 2.9. As shown in Figure 2.9 (inset), the ratio between the 
rate of NADH oxidation and that of O2 reduction is (1.91 ± 0.05) for G65Y-CuBMb(+6). This 
result is consistent with the low percentage of H2O2 directly probed by the above 
Figure 2.9. (a) Measurement of O2 reduction and H2O2 production in the O2 reduction 
reaction. (b) Representative kinetic UV-visible spectra of reaction solution with 100 μM 
NADH, sampled at 0.5 s interval over 100 s. NADH oxidation and oxygen reduction 




electroanalytical method. Together, both results strongly suggest that the O2 reduction carried out 
by the G65Y-CuBMb(+6) is a 4e
- process producing H2O, like in native oxidases. Finally, 50 nM 
G65Y-CuBMb(+6) was able to reduce 220 μM of O2 in the reaction system (Figure 2.5), 
corresponding to more than 4,400 turnovers. 
The kinetic spectroscopic study attributes the oxygen reduction activity to the efficient 
electron transfer between cyt b5 and G65Y-CuBMb(+6) and Mb(+6). Moreover, G65YMb(+6) 
mutants show better specificity (93%) towards a four-electron reduction of oxygen to water, 
compared to previous Mb-based oxygen reductase systems (75% in G65Y-CuBMb and 22% in 
Mb, using ascorbate/TMPD) without the charge-reversal mutations. The specificity of the 
oxygen reduction reaction is in part a competition between the release of partially reduced 
oxygen species from the heme site in the form of ROS and the full reduction of heme-bound 
oxygen by four incoming electrons generating water. Mutants with the same active site residues 
(G65Y-CuBMb(+6) compared to G65Y-CuBMb) are anticipated to have similar oxygen affinity, 









































Figure 2.10. Oxygen reduction and hydrogen peroxide production rate of G65Y-
CuBMb(+6) and G65Y-CuBMb. 
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reductant, the electron transfer is slower, partially reduced oxygen species might dissociate from 
the heme site before getting fully reduced by four electrons. The enhancement of the electron 
transfer component of the competitive reactions is postulated to be the major reason of high 
specificity of G65Y-CuBMb(+6) and Mb(+6) towards water production. 
CONCLUSION 
In conclusion, we have succeeded in engineering a myoglobin, which natively binds O2 
reversibly, into an oxidase that displays the O2 reduction activity of a native oxidase, with a 
similar rate and 4e reduction process. We achieved the goal by enhancing the ET rates by 
engineering more favorable electrostatic interactions between the Mb and its redox partner, cyt 
b5, in addition to introducing similar structural elements (conserved His and Tyr) into Mb. By 
demonstrating our ability to design proteins that match the activities of native enzymes, we have 
obtained deeper understanding of structural features important for oxidase activity, which may 
allow engineering artificial enzymes for biochemical and biotechnology applications such as 
more efficient ORR catalysts for biofuel cells.    
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CHAPTER 3: REDOX TUNING OF SMALL LACCASE FOR ELECTROCATALYTIC 
OXYGEN REDUCTION REACTION 
 
INTRODUCTION 
Fuel cell is an electrochemical device that generates electrical current from oxidation of 
fuel at the anode and the reduction reaction at the cathode.1 Fuel cell has drawn increasing 
attention because of its high theoretical efficiency (over 90%), which circumvents the limitation 
of a Carnot engine.  However, the current fuel cells present an efficiency below 50%. This 
substantial deviation from the theoretical limit primarily results from the large overpotential 
(500-600 mV) of the cathode reaction, which is typically oxygen reduction reaction (ORR).1 As 
such, designing a potent ORR catalyst to decrease the overpotential is crucial for the 
development of fuel cells. Towards this goal, much progress has been made using metal2–4 or 
carbon based materials56 (bulk metal, alloy, nanoparticle et al) and metal complexes,7–9 with 
platinum nanoparticles showing the benchmark overpotential 300 mV. The most active ORR 
catalyst (80 mV overpotential) to date is Trametes versicolor laccase,10,11 a multi-copper oxidase 
from fungi, which catalyzes the four-electron reduction of oxygen to water at the tri-nuclear 
copper center (TNC), coupled to the promiscuous oxidation of small molecule substrates near the 
Type 1 copper center (T1 Cu).12  
Despite the success in using various fungal laccases as ORR catalysts, further application 
is limited by their relatively low stability, low current density because of the large footprint on 
the electrode surface, and more importantly, the lack of a recombinant expression system for the 
glycosylated fungal laccases. To overcome these limitations, several studies have been focused 
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on studying the mechanism of laccase function characterizing and expressing new laccases and 
engineering existing laccases to have higher activity or stability. Of particular interest is a small 
laccase (SLAC) from Streptomyces coelicolor (Figure 3.1).13 SLAC is a bacterial protein that can 
be easily expressed in Escherichia coli, making it more amenable to common genetic 
engineering techniques. More importantly, SLAC consists of two domains and therefore has the 
potential to display higher current density of active sites on the electrode compared with the 
typical three-domain laccases (~46 by 22 Å surface compared to 50 by 45 Å per 1 active site in 
normal fungal laccases).  
However, the onset potential of SLAC is much lower than fungal laccases.14 The 
reduction potential of the T1 Cu in SLAC is 370 mV which is also lower than Tv laccase (800 
mV). The oxygen reduction reaction starts from the fully reduced laccase binding oxygen. In the 
Figure 3.1 The structural overlay of with HP-Az and Trametes versicolor laccase. (blue) small 
laccase; (yellow) Trametes versicolor laccase; (cyan) high-potential azurin mutant (HP-Az). 
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catalytic cycle, the native intermediate needs to accept electrons from the electrode to regenerate 
the fully reduced enzyme.15 During the interfacial electron transfer, the T1 Cu is the first entry 
site for the incoming electrons, therefore, the reduction potential of the T1 Cu center determines 
the minimal reducing potential required to inject the electrons to the T1 Cu center to supply the 
oxygen reduction. Herein we report tuning the reduction potential of the T1 Cu to increase the 
onset potential of oxygen reduction.  
We have demonstrated the rational tuning of reduction potential of T1 Cu protein azurin 
by 600 mV, by modulating the secondary coordination sphere interactions, such as dipole 
interactions and hydrogen bonds.16,17 The structural overlay of the T1 Cu domain of SLAC with 
both Trametes versicolor laccase (780 mV) and the high potential azurin (960 mV)17 suggests 
that V290N and Y230N mutation can potentially increase the reduction potential of T1 Cu by 
imposing a positively orientated dipole towards the Cu center, similar to the effect of F114N in 
azurin. In addition, mutation of residues M198 and Y230 to a hydrophobic Leu or Phe will 
increase the hydrophobicity of the site which favors the low oxidation state and thereby increase 
the reduction potential. Y230F, Y229F, S292F can also increase the reduction potential by 
further desolvating the Cu center. 
MATERIALS AND METHODS 
Gene construction  
The gene of SLAC was subcloned into pET22b plasmid with N-terminal His-tag. The 
mutations were introduced into SLAC by site-directed mutagenesis with the following primers: 
y229f_f CAC GCA TGG CGA ATT TTA CCA CAC CTT TCA CAT GC 
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y229f_r GCA TGT GAA AGG TGT GGT AAA ATT CGC CAT GCG TG 
s292f_f CAT TGC CAC GTT CAA TTT CAT TCC GAT ATG GGC 
s292f_r GCC CAT ATC GGA ATG AAA TTG AAC GTG GCA ATG 
M198L-f CCA TCG TTT TCA ACG ATC TGA CCA TCA ACA ACC GTA AAC C  
M198L-r GGT TTA CGG TTG TTG ATG GTC AGA TCG TTG AAA ACG ATG G  
T232V-f GCG AAT ATT ACC ACG TGT TTC ACA TGC ATG GTC ACC -3' 
T232V-r GGT GAC CAT GCA TGT GAA ACA CGT GGT AAT ATT CGC -3' 
V290T-f GGA TGT ATC ATT GCC ACA CCC AAA GTC ATT CCG ATA TGG -3' 
V290T-r CCA TAT CGG AAT GAC TTT GGG TGT GGC AAT GAT ACA TCC -3' 
T199F  CCA TCG TTT TCA ACG ATA TGT TTA TCA ACA ACC GTA AAC CGC 
T199F  GCG GTT TAC GGT TGT TGA TAA ACA TAT CGT TGA AAA CGA TGG 
T199V  CCA TCG TTT TCA ACG ATA TGG TGA TCA ACA ACC GTA AAC CGC 
T199V  GCG GTT TAC GGT TGT TGA TCA CCA TAT CGT TGA AAA CGA TGG 
M223F CCG CGT TGA AAT TGT CTT TAT CAC GCA TGG CG 
M223F  CGC CAT GCG TGA TAA AGA CAA TTT CAA CGC GG 
M223L GCG TTG AAA TTG TCC TGA TCA CGC ATG GCG 
M223L  CGC CAT GCG TGA TCA GGA CAA TTT CAA CGC 
T225V  CGT TGA AAT TGT CAT GAT CGT GCA TGG CGA ATA TTA CCA CAC C 
T225V  GGT GTG GTA ATA TTC GCC ATG CAC GAT CAT GAC AAT TTC AAC G 
T263V  CGT TAT TGA TAA TAA AAT CGT GGG CCC GGC AGA CTC G 
T263V  CGA GTC TGC CGG GCC CAC GAT TTT ATT ATC AAT AAC G 
M296F CGT TCA AAG TCA TTC CGA TTT TGG CAT GGT GGG TCT GTT CC 
M296F  GGA ACA GAC CCA CCA TGC CAA AAT CGG AAT GAC TTT GAA CG 
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M296L CGT TCA AAG TCA TTC CGA TCT GGG CAT GGT GGG TCT GTT CC 
M296L  GGA ACA GAC CCA CCA TGC CCA GAT CGG AAT GAC TTT GAA CG 
M198L-f CCA TCG TTT TCA ACG ATC TGA CCA TCA ACA ACC GTAAAC C 
M198L-r GGT TTA CGG TTG TTG ATG GTC AGA TCG TTG AAA ACG ATG G 
T232V-f GCG AAT ATT ACC ACG TGT TTC ACA TGC ATG GTC ACC  
T232V-r GGT GAC CAT GCA TGT GAA ACA CGT GGT AAT ATT CGC  
V290T-f GGA TGT ATC ATT GCC ACA CCC AAA GTC ATT CCG ATA TGG  
V290T-r CCA TAT CGG AAT GAC TTT GGG TGT GGC AAT GAT ACA TCC  
Protein expression and purification  
SLAC and its mutants were expressed and purified by standard His-tag purification 
protocol. The plasmid encoding SLAC was transformed into BL21(DE3) cells and incubated at 
37 C overnight. A single colony was added into 50 mL LB medium with Ampicillin 100 mg mL-
1 and shake at 37 C for 6~8 h. The starter culture was added into 2XYT medium 4 L (per L 
contains tryptone 32 g, yeast extract 20 g, NaCl 10 g) with Amp 100 mg/L. The cell was cultured 
at 30 C, shaking at 220 rpm for 15 h. The expression was induced by the addition of IPTG 0.4 
mM and CuSO4 0.25 mM at 25 C overnight. 
The cells were harvested and resuspended in lysis buffer (per L contains CuSO4 1 mM, 
Tris 2.42 g 20 mM, NaCl 17.54 g 300 mM, imidazole 0.68 g 10 mM adjust to pH 8.0 with 
NaOH/HCl) by shaking at 4 C for 1 h. The cells were lysed by sonication for 12 min on ice. The 
cell lysate was centrifuged at 13,000 rpm for 30 min. The Ni-NTA sepharose (Qiagen) was pre-
equilibrated with lysis buffer and batch bound to the supernatant by shaking at 4 C for 1 h. The 
column was washed with 50 mL lysis buffer and 50 mL washing buffer (per L contains NaHPO4 
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6.90 g 50 mM, NaCl 17.54 g 300 mM, imidazole 20 mM adjust to pH 8.0 with NaOH) and 
eluted with elution buffer (per L contains NaHPO4 6.90 g 50 mM, NaCl 17.54 g 300 mM, 
imidazole 17.00 g 250 mM adjust to pH 8.0 with NaOH). The protein was concentrated to 5 mL 
and purified by size exclusion chromatography eluted with NaPi 100 mM pH 7 and verified by 
SDS-PAGE.  
Spectroscopic characterizations 
UV-vis spectra were recorded on an HP 8453 diode array spectrometer or a Cary 5000 
spectrometer. Extinction coefficients were determined by spin counting. EPR spectra were 
collected on a Varian E-122 spectrometer at 30 K under He flow. Experimental parameters: 
frequency: 9.17 GHz; power: 0.2 mW; modulation: 4 Gauss. EPR spectra were simulated with 
SIMPOW6. 
Poise potential redox titration  
The SLAC mutants were degassed, transferred into the glove bag and diluted to 
approximately 0.1 mM with a total volume of 100 L. The protein was mixed with 5 mM 
potassium ferricyanide in a cuvette and titrated with 500 mM potassium ferrocyanide solution 
from 0.5 to 25 mM. 
Electrode modification and electrocatalysis  
The electrocatalysis was performed on gold electrodes modified with self-assembled 
monolayers (SAM). Specifically, the gold electrodes were polished with diamond suspension (9 
m, 3 m, 0.25 m) on polishing cloth TexMet C, and sonicated in water for 1 min after each 
polishing. The polished electrode was cleaned in 0.5 M H2SO4, and electrochemically roughened 
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by redox cycling in 0.5 M KCl. The roughen gold electrode was dipped into a solution 
containing 10 M 8-mercaptooctanoic acid and 1 mM 6-mercapto-1-hexanol in ethanol, 
incubated for 30 min, and rinsed with ethanol. The thiol modified electrode was activated by 
incubating in 40 mM 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride  
(EDC) and 10 mM N-hydroxysuccinimide (NHS) in 50 mM 2-(N-
morpholino)ethanesulfonic acid (MES) pH 4.6 for 30 min. The activated electrode 
was treated with 5 mM 2-aminoanthracene and 1 M triethylamine in ethanol. The 
result Au-SAM electrode was dipped into the 15 M SLAC solution in 100 mM 
NaPi pH 7.0 for 2 h.  
The electrocatalysis was measured by cyclic voltammetry in a standard three -
electrode chamber, with a Ag/AgCl electrode (230 mV vs SHE) as the reference 
electrode and a platinum wire as the counter electrode. The cyclic voltammetry was 
performed in either argon or oxygen saturated 100 mM NaPi pH 7.0 buffer.  
RESULTS AND DISCUSSION 
The designed mutations retain the spectroscopic features of the wild type SLAC in both 
UV-vis and EPR spectra. Similar to WT SLAC, all the mutants retain the 590 nm ligand to metal 
charge transfer band from the T1 Cu center, the 750 nm d-d transition of the T2 Cu center and 
the 330 nm shoulder indicative of intact T3 Cu centers (Figure 3.2). The EPR spectra showed a 


























Figure 3.2. Representative UV-vis spectra of SLAC mutants. 













During the redox titration, the 590 nm LMCT band progressively decreases after each 
addition of K4[Fe(CN)6] indicating the reduction of the T1 Cu center (Figure 4). Nernst fitting 
showed that M198L, Y230F, V290N increase the reduction potential by 34, 45 and 134 mV 
respectively. The triple mutant M198L/Y230F/V290N shows a reduction potential of 554 mV as 
 gx gy gz Ax Ay Az Weight 
wt (type1) 2.0305 2.0332 2.2151 19 5 72 100 
wt(type2) 2.053 2.049 2.251 65 14 180 99 
mut(type1)d 2.0296 2.0342 2.2119 14 4 74 100 
mut(type2)d 2.050  2.051 2.288 87 14 153 58 
mut(type1)e 2.0305 2.0325 2.2120 13 5 73 100 
mut(type2)e 2.044 2.047 2.238 43 13 198 104 
mut(type1)f 2.0317 2.0343 2.2156 21 6 70 100 
mut(type2)f 2.054 2.052 2.250 66 17 177 82 
mut(type1)g 2.0289 2.0356 2.2094 17 7 71 100 
mut(type2)g 2.048 2.048 2.249 41 14 190 98 
Table 3.1. The simulated parameters of EPR spectroscopy 
 
Figure 3.4. The redox titration and Nernst fitting of wild type SLAC. 
54 
 
compared to 370 mV in wild type SLAC, consistent with the additive effects in redox tuning. 
The choice of the single molecule layer on the Au electrode is critical to the 
electrocatalysis. The modifications we have investigated include 1-hexanethiol, cysteamine. The 
electrocatalysis was performed on Au-SAM electrode modified with anthracene, a substrate 
analog of SLAC, and backfilled with hydrophilic 6-mercapto-1-hexanol (Figure 3.5). The 
hydrophobic substrate pocket near the T1 Cu preferentially interacts with anthracene, and 
therefore orients T1 Cu close to the electrode to serve as the electron entry site.  
 
The wild type SLAC and the mutants showed a uA reduction current under oxygen 
atmosphere which is absent under argon, indicating the current corresponds to oxygen reduction 
reaction. The Au-SAM electrode does not show observable current (Figure 3.5). In addition, 
replacing the anthracene with anthracene quinone yields the same catalytic current, suggesting 
the catalytic activity comes from the protein layer (Figure 3.6).  
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Figure 3.6. The electrocatalytic oxygen reduction on Au-SAM electrode with or without the 
protein layer. 





The mutants with higher reduction potentials of the T1 Cu center also showed an 
increased onset potential. For instance, the M198L/Y230F/V290N mutant exhibits an additive 
effect in increasing the onset potential by 180 mV (Figure 3.8) which is also consistent with the 
change in the reduction potential of the T1 Cu center. The overpotential of 
M198L/Y230F/V290N at pH 7 is 180 mV which surpasses the classic platinum-based catalysts. 
Plotting the onset potential of oxygen reduction versus the reduction potential of the T1 Cu 
center reveals a positive correlation (Figure 3.9), which confirms our working hypothesis that the 
reduction potential of the T1 Cu center determines the onset potential of the oxygen reduction 
reaction. 





















Figure 3.8. The electrocatalytic oxygen reduction by wild type SLAC and the mutants with 




Figure 3.9. The positive correlation between the onset potential of oxygen reduction 




In summary, we demonstrated the redox tuning of a multi-copper oxidase by non-
covalent interactions in the secondary coordination sphere and validated the hypothesis that the 
reduction potential of T1 Cu plays a crucial role in defining the onset potential of ORR. The 
results provide a viable approach to decrease and ultimately diminish the ORR overpotential for 
biofuel cell application. Future work includes introducing hydrophobic methionine analogs in the 
primary coordination sphere by expressed protein ligation to increase the reduction potential. 
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CHAPTER 4: STUDY THE EFFECTS OF THE AXIAL METHIONINE ON THE CU-S 
INTERACTION IN SMALL LACCASE 
 
INTRODUCTION 
The axial methionine plays an important role in determining the electronic structures and 
therefore the reduction potentials of cupredoxins such as azurin.1,2 There have been extensive 
spectroscopic, electrochemical and computational studies on the axial Met121 mutants. Karlsson 
and coworkers reported an additional charge transfer band in Met121 mutants except for M121L 
azurin.3 The computational study from Solomon and coworkers suggested that structural 
distortion of a blue copper center can lead to a mixing a - and −interactions in the Cu-S(Cys) 
bond which give rise to a charge transfer band in 600 and 450 nm region respectively (Figure 
4.1).4 Lu and coworkers replaced the axial Met121 with a series of isostructural unnatural amino 
acid analogues with various hydrophobicity, namely, glutamate, oxomethionine (OxM), 
difluoromethionine (DFM), trifluoromethionine (TFM), selenomethionine (SeM), and norleucine 
(Nle) using expressed protein ligation and observed linear increase in the reduction potentials 
over 227 mV range as the hydrophobicity of the axial ligand increases.1,2 Additionally, mutating 
Met121 to glutamate, aspartate or leucine result in a 170 mV variation in the reduction potential.5  
The significant impact of Met121 mutation on tuning the reduction potential is attributed 
to two factors: (1) the hydrophobic axial residues such as Leu preferentially stabilizes the Cu+ 
state thus increases the reduction potential (2) the axial Met121 is involved in the hydrophobic 
interaction with Phe15 and Met13 in the hydrophobic loop, as such, any mutation may perturb 
the conformation of azurin. Interestingly, the same mutations at Met123, the corresponding axial 
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position in CuAAz leads to only 24 mV change in the reduction potentials of the CuA center.
5 
The insensitivity to the axial ligand variation is attributed to the strong Cu2S2(Cys) diamond core 
that prevents dramatic structural perturbation by the axial mutation. 
In this work, we expressed and purified a series of Met298 mutants of small laccase 
(SLAC) to explore how the axial interactions affect the spectroscopy, reduction potential and 
catalytic activity of SLAC. 
MATERIALS AND METHODS 
Gene construction  
The gene of SLAC was subcloned into pET22b plasmid with N-terminal His-tag. The 
mutations were introduced into SLAC by site-directed mutagenesis with the following primers: 
 
Figure 4.1. The comparison between the UV-vis spectra of blue, green and red copper 
proteins. The red shift in the charge transfer band indicates a mixing of  interaction. 
Reprinted from Ref. 4. 
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Protein expression and purification  
SLAC and its mutants were expressed and purified by standard His-tag purification 
protocol. The plasmid encoding SLAC was transformed into BL21(DE3) cells and incubated at 
37 C overnight. A single colony was added into 50 mL LB medium with Ampicillin 100 mg mL-
1 and shake at 37 C for 6~8 h. The starter culture was added into 2XYT medium 4 L (per L 
contains tryptone 32 g, yeast extract 20 g, NaCl 10 g) with Amp 100 mg/L. The cell was cultured 
at 30 C, shaking at 220 rpm for 15 h. The expression was induced by the addition of IPTG 0.4 
mM and CuSO4 0.25 mM at 25 C overnight. 
The cells were harvested and resuspended in lysis buffer (per L contains CuSO4 1 mM, 
Tris 2.42 g 20 mM, NaCl 17.54 g 300 mM, imidazole 0.68 g 10 mM adjust to pH 8.0 with 
NaOH/HCl) by shaking at 4 C for 1 h. The cells were lysed by sonication for 12 min on ice. The 
cell lysate was centrifuged at 13,000 rpm for 30 min. The Ni-NTA sepharose (Qiagen) was pre-
equilibrated with lysis buffer and batch bound to the supernatant by shaking at 4 C for 1 h. The 
column was washed with 50 mL lysis buffer and 50 mL washing buffer (per L contains NaHPO4 
6.90 g 50 mM, NaCl 17.54 g 300 mM, imidazole 20 mM adjust to pH 8.0 with NaOH) and 
eluted with elution buffer (per L contains NaHPO4 6.90 g 50 mM, NaCl 17.54 g 300 mM, 
imidazole 17.00 g 250 mM adjust to pH 8.0 with NaOH). The protein was concentrated to 5 mL 
and purified by size exclusion chromatography eluted with NaPi 100 mM pH 7 and verified by 
SDS-PAGE.  
Spectroscopic characterizations 
UV-vis spectra were recorded on an HP 8453 diode array spectrometer or a Cary 5000 
spectrometer. Extinction coefficients were determined by spin counting. EPR spectra were 
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collected on a Varian E-122 spectrometer at 30 K under He flow. Experimental parameters: 
frequency: 9.17 GHz; power: 0.2 mW; modulation: 4 Gauss. EPR spectra were simulated with 
SIMPOW6. 
Poise potential redox titration  
The SLAC mutants were degassed, transferred into the glove bag and diluted to 
approximately 0.1 mM with a total volume of 100 mL. The protein was mixed with 5 mM 
potassium ferricyanide in a cuvette and titrated with 500 mM potassium ferrocyanide solution 
from 0.5 to 25 mM. 
Electrode modification and electrocatalysis  
The electrocatalysis was performed on gold electrodes modified with self-assembled 
monolayers (SAM). Specifically, the gold electrodes were polished with diamond suspension (9 
m, 3 m, 0.25 m) on polishing cloth TexMet C, and sonicated in water for 1 min after each 
polishing. The polished electrode was cleaned in 0.5 M H2SO4, and electrochemically roughened 
by redox cycling in 0.5 M KCl. The roughen gold electrode was dipped into a solution 
containing 1 mM 6-mercaptohexanmol in ethanol. The result Au-SAM electrode was 
dipped into the 15 M SLAC solution in 100 mM NaPi pH 7.0 for 2 h.  
The electrocatalysis was measured by cyclic voltammetry in a stand ard three-
electrode chamber, with a Ag/AgCl electrode (230 mV vs SHE) as the reference 
electrode and a platinum wire as the counter electrode. The cyclic voltammetry was 




RESULTS AND DISCUSSION 
The crystal structure of M298L reveals an unexpected water network at the T1 Cu center 
(Figure 4.2). The coordinating water molecule provides a stronger axial interaction which 
potentially contributes to a stronger sigma interaction. We attempted to maintain the 
hydrophobic environment of the T1 Cu by designed a series of complimentary mutations. The 
structural overlay with fungal laccases from Trametes versicolor and Rigidoporus lignosus 
showed a conserved Phe residue which occupies the position corresponding Met198 (Figure 4.3). 
In addition, Thr199 forms a hydrogen bonding network with the water chain and potentially 
stabilizes the coordinating water, therefore we designed T199F mutation to block the access of 
external water ligand based on the structural overlay with the high potential fungal laccase. The 
beta-turn is a potential site where the coordinating water access the active site, thus a bulky and 
hydrophobic Phe can block the water entrance (Figure 4.3). However, a caveat here is that the 




Thr199 is solvent exposed and the HOH interacts primarily with the backbone, so this mutation 
may not exhibit any effect. 
An alternative pathway for the water molecule to access the Cu center is through the 
opposite side of the beta barrel from residues such as from Val290, therefore introducing more 
steric hinderances and hydrophobic residues such as Phe/Ile may prevent HOH entering by 
sterics (Figure 4.3). Additionally, the  electrons from Phe195 may stabilize the proximal water 
binding, as such, a hydrophobic yet non-aromatic Ile at this place can diminish this effect. 
However, these complementary mutations failed to maintain the blue copper feature of the T1 Cu 
center, possibly because the conformational dynamics of the protein might compensate for the 
designed effects. Furthermore, we have incorporated V290N mutation which was shown to 





Figure 4.3. Designed complimentary mutations to retain the hydrophobicity of the Cu 
center. Red: Trametes versicolor, PDB 1GYC. Blue: Rigidoporus lignosus, PDB 1V10. 
Colored: SLAC PDB: 3CG8. 
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The axial methionine was mutated to hydrophobic residues like Leu, Phe, Ile or Ala and 
hydrophilic residue Asn and the resultant mutants were characterized by UV-vis and EPR 
spectroscopy. The UV-vis spectra of all Met 298 mutants showed two ligand to metal charge 
transfer bands at 420-440 nm and 560-590 nm from the mononuclear copper center (Figure 4.4), 
whereas WT SLAC only shows a 590 nm LMCT band from the T1 Cu center. Similar to WT 
SLAC, all the mutants retain the 750 nm d-d transition and a 330 nm shoulder which are 
indicative of intact T2 and T3 Cu centers. The additional MLCT band at 420-440 nm transition 
suggests a  interaction in Cu-S(Cys) bond in additional to the  interaction as previously 
observed in mononuclear cupredoxins. The hyperfine interactions in EPR shows greater 






























Figure 4.4. The UV-vis spectra of M298X SLAC mutants. 
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rhombicity in the T1/1.5 Cu which is consistent with the coexistence of the - and -interactions. 
The EPR simulation reveals that most M2988 mutants maintain both a T1 and a T2 Cu 
center despite of relatively large hyperfine interaction (Figure 4.5) with three exceptions, 
M298L/V290N, M198F/M298F and M298F/V290N (Figure 4.6). M298L/V290N mutant was 
modeled to be a 1:1 mixture of two distinct T2 Cu centers, whereas the other two mutants can be 
best fit as a T1.5 and a T2 Cu centers. The greater rhombicity of the three mutants suggest a 
dramatic change in the coordination geometry of the origin T1 Cu center. 
 
  
Figure 4.5. The EPR spectra of M298X SLAC mutants. 
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Various attempts have been made to measure the reduction potential of the T1 Cu center 




+ and F114P/M121E azurin. Neither 
[RuIII(NH3)5Cl]
2+/[RuII(NH3)5Cl]
+ nor F114P/M121E azurin could not form an effective electron 
transfer interface with the M298X mutants. K3[Fe(CN)6]/K4[Fe(CN)6] still effectively reduces or 
oxidizes the proteins, however, the effective range of the Nernst fitting is 100 mV around the 
standard reduction potential of the mediators which is 430 mV, thus the mediator pair only 
M298F/V290N 
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Figure 4.6. The representative experimental and simulated EPR spectra of M298X laccase 
mutants. M298L/V290N was simulated as a 1:1 mixture of two T2 Cu centers whereas 




applies to the mutants with relatively high reduction potential such as M298L/V290N, which is 
measured to be 496 mV (Figure 4.7), whereas the low potential variants such as M298A cannot 
be reduced by K4[Fe(CN)6]. 
The cyclic voltammetry was carried out on Au electrode modified with a hydrophilic 6-
mercapto-1-hexanol layer to ensure the stability of the proteins on the surface. M298A showed a 
much lower reduction potential (160 mV vs SHE) compared to the wild type enzyme which 
explains the lack of catalytic activity. Some mutants showed a reversible peak at 310 mV vs SHE 
and an irreversible reduction peak at 460 mV (Figure 4.8, 4.9). It is currently difficult to assign 
each peak to a specific redox event. Further spectroelectrochemistry experiments will be 
appropriate to answer these questions. 






































Equation y = a + b*x
Plot F
Weight No Weighting
Intercept 496.15379 ± 0.75157
Slope 78.49553 ± 1.59404












The electrocatalytic oxygen reduction was measured on the same Au-SAM electrode. The 
cyclic voltammogram showed a catalytic current under oxygen atmosphere which is absent under 
Ar atmosphere, indicating the catalytic current corresponds to oxygen reduction reaction (Figure 
4.10). The onset potential of oxygen reduction exhibits a positive correlation with the A// 
hyperfine of the T1 copper (Figure 4.11). The hyperfine coupling originates from the coupling 
between Cu nuclei and electron spin and a greater hyperfine coupling indicates a larger spin 
density localized on the Cu center, i.e., the Cu is more electron deficient resulting in a higher 
reduction potential. 



































































Equation y = a + b*x
Plot G
Weight No Weighting
Intercept 319.38403 ± 10.2221
Slope 0.34275 ± 0.04577




Figure 4.10. The electrocatalytic oxygen reduction reaction on Au-SAM electrode modified 
by M298X mutants at pH 4. 
Figure 4.11. The correlation between the onset potential and the reduction potential of 




In summary, we designed a series of mutations to modulate the axial interactions in small 
laccase and observed the correlation between the onset potential of the oxygen reduction reaction 
and the A// hyperfine of the T1 copper center. The presented result confirms the critical role of 
the axial interactions in defining the electronic structure and redox properties of cupredoxins and 
furthermore links the local effect with the enzymatic activity. 
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CHAPTER 5: DESIGN OF AN ARTIFICIAL METALLOENZYME BY GENETIC 
INCORPORATION OF A METAL CHELATOR FOR REGIOSELECTIVE 
EPOXIDATION 
INTRODUCTION 
Lipid epoxides are the metabolites of lipids ubiquitously found in nature, which are 
converted to dihydroxyl lipids by epoxide hydrolases.1–4 Both lipid epoxides and dihydroxyl 
lipids have drawn increasing attentions because of their wide variety of biologically functions 
discovered recently.5–7 The epoxidation of polyunsaturated fatty acid is a family of lipid 
particularly interesting to chemist not only because of their diverse functions in inflammation 
and heart health but also because of the great synthetic challenge of the regioselectivity and 
enantioselectivity. 
Figure 5.1. Overview of the CYP epoxygenase-mediated metabolism of endocannabinoids. 
Reprinted from reference 5. 
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The epoxidation of polyunsaturated fatty acids is catalyzed by P450 monooxygenases, 
such as CYP2J2 which is predominantly produced in heart tissue. CYP2J2 epoxidizes the C=C 
double bonds in native ω-3 PUFAs such as docosahexaenoic acid (DHA) and eicosapentaenoic 
acid (EPA) forming regioisomers of epoxyeicosatetraenoic acid-ethanolamide (EEQ-EA) and 
epoxydocosapentaenoic acid-ethanolamide (EDP-EA) with the epoxidation happening on various 
positions (Figure 5.1).5 The resultant products have been shown to exhibit anti-inflammatory5 
and antiangiogenic functions.8 The product distribution shows that the native enzyme 
preferentially oxidizes the substrate from the hydrophobic end without additional 
regioselectivity.  
From a chemistry point of view, it will be interesting and challenging to design a catalyst 
with both regioselectivity and enantioselectivity. For olefin in general, there are several catalysts 
containing base metals such as iron and catalyzing the epoxidation reaction. Several outstanding 
examples are a mononuclear [FeII(mep)(CH3CN)2](ClO4)2 (mep = N,N’–dimethyl-N,N’-bis(2- 
pyridylmethyl)-ethane, 1,2-diamine) complex by Jacobsen and coworkers,9 Fe(PDP) by White 




there are several catalysts generated in situ by mixing FeCl3.6H2O with ligands such as pyridine-
2,6-dicarboxylic acid.12,13 However, these enzymes do not impart regioselectivity over multiple 
C-C double bonds. 
A potential approach to enable regioselectivity is to utilize a protein scaffold to 
accommodate the substrates near the active site with one C=C double bond within the closest 
proximity to the catalytic center. The protein scaffold we selected is cellular retinoic acid-
binding protein II (CRABP II), which binds retinoic acid binding protein within the cavity a β-
barrel fold. The 1.48 Å resolution crystal structure of CRABP II reveals a well-defined binding 
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site for its native substrate retinoic acid.14 To convert CRABP II from a lipid binding protein to 
an epoxidase, a metal chelating unnatural amino acid bipyridylalanine was incorporated in Phe15 
position to serve as a bidentate ligand to bind an iron cofactor (Figure 5.2). 
MATERIALS AND METHODS 
Gene construction  
The gene of CRABPII was subcloned into pET28b plasmid with N-terminal His-tag by 
Gibson assembly. The mutations were introduced into CRABPII by site-directed mutagenesis. 
The primers used are: 
CRABPII_f CCC TCT AGA AAT AAT TTT GTT TAA CTT TAA GAA GGA GAT ATA 
CAT ATG CCA AAC TTC TCT GGC 
Figure 5.2. The crystal structure of CRABP II with retinoic acid bound. (PDB: 2FR3) 
The potential sites for metal incorporation was highlighted. 
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CRABPII_f GGG TCT ACG TCC GAG AGC TGG TGC CGC GCG GCA GCC ACC ACC 
ACC ACC ACC ACT G 
vector-f CAG TGG TGG TGG TGG TGG TGG CTG CCG CGC GGC ACC AGC TCT 
CGG ACG TAG ACC C 
vector-r GCC AGA GAA GTT TGG CAT ATG TAT ATC TCC TTC TTA AAG TTA 
AAC AAA ATT ATT TCT AGA GGG  
15TAG-f CCG ATC GGA AAA CTA GGA GGA ATT GCT CAA AGT GCT GGG GG  
15TAG-r CCC CCA GCA CTT TGA GCA ATT CCT CCT AGT TTT CCG ATC GG 
Transformation  
The plasmids PET22b-15Febpy-CRABP II and PEVOL-aaRS-BpyAla were co-
transformed into BL21(DE3) cell by incubating on ice for 30 min and heat shocking at 42 C for 
10 s. The cells were recovered in LB media at 37 C 220 rpm for 1 h and plated on LB plates with 
kanamycin 50 mg/L and chloramphenicol 33 mg/L. The cells were incubated at 37 C overnight. 
Protein expression and purification  
CRABP II and its mutants were expressed and purified by standard His-tag purification 
protocol. A single colony was inoculated into 5 mL growth in LB medium with Kanamycin 50 
mg/L and chloramphenicol 33 mg/L. After 8 h, the starting culture was resuspended into 500 mL 
growth in TB medium until O.D. 0.8 typically after 5~6 h at 37 C. Add bpyAla 1mM dissolved 
in KPi pH 8 and decrease the temperature to 16 C and shake for 1h. Induce with IPTG 1mM, 
arabinose 0.04% (w/v), overexpress for 24 h. 
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The cells were harvested and resuspended in lysis buffer (per L contains Tris 2.42 g 20 
mM, NaCl 17.54 g 300 mM, imidazole 0.68 g 10 mM adjust to pH 8.0 with NaOH/HCl) by 
shaking at 4 C for 1 h. The cells were lysed by sonication for 12 min on ice. The cell lysate was 
centrifuged at 13,000 rpm for 30 min. The Ni-NTA sepharose (Qiagen) was pre-equilibrated 
with lysis buffer and batch bound to the supernatant by shaking at 4 C for 1 h. The column was 
washed with 50 mL lysis buffer and 50 mL washing buffer (per L contains NaHPO4 6.90 g 50 
mM, NaCl 17.54 g 300 mM, imidazole 20 mM adjust to pH 8.0 with NaOH) and eluted with 
elution buffer (per L contains NaHPO4 6.90 g 50 mM, NaCl 17.54 g 300 mM, imidazole 17.00 g 
250 mM adjust to pH 8.0 with NaOH). The protein was concentrated to 5 mL and purified by 
size exclusion chromatography eluted with NaPi 100 mM pH 7 and verified by SDS-PAGE.  
Fluorometric titration to determine the binding affinity of retinoic acid in CRABPII 
The binding affinity was measured as previously reported.15 Briefly, the as-purifed 
CRABP II was exchanged to 20 mM potassium phosphate buffer with 100 mM potassium 
chloride pH 7.0 to a final concentration of 0.5 M. The retinoic acid working solution was 
diluted to 30 M dissolved in ethanol. The concentration was calculated by extinction coefficient 
20 mM-1 cm-1 at 280 nm for CRABP II and 45 mM-1 cm-1 at 336 nm for retinoic acid. The 
samples were excited at 283 nm and titrated with aliquots of retinoic acid. 
Activity Assay  
The epoxidation reaction was carried out in 100 uL Chelex cleaned Bis-Tris 100 mM pH 
7. The concentration of 15FeBpy-CRABP II is 80 M. Add 0.8 uL 10 mM stock solution of 
retinoic acid, EPEA or DHEA dissolved in DMSO to reach a final concentration of 80 uM and 
incubate at RT for 20 min to maximize lipid binding. Add 0.8 uL 10 mM stock solution of 
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H2O2, or HOOAc, or PhIO, or tBuOOH to a final concentration of 80 uM and incubate at 37 C 
for 1 h. 
The reaction was quenched with an addition of 20 uL HCOOH and the product was 
extracted with EtOAc 100 uL. The mixed solvent was vortex for 1 min and centrifuge at 15000 
rpm for 10 min. Repeat the extraction three times and combine the organic layer. The resultant 
solution was evaporated in Ar and reconstitute in 90% EtOH for HPLC-MS/MS analysis. 
RESULTS AND DISCUSSION 
 The BpyAla ligand was genetically incorporated into the Phe15 position by Amber codon 
suppression method as shown in SDS-PAGE analysis (Figure 5.3) and MALDI mass 
spectrometry (Figure 5.4, 5.5). There a major band at 16 kDa shown on the SDS-PAGE after Ni 
affinity purification which is consistent with the target protein. Further purification by size 
exclusion chromatography showed a cleaner band with a molecular weight matching the WT 
protein. To prevent any adventitious metal binding by the 6xHis tag, the purified protein was 
stirred with Thrombin at room temperature overnight to cleavage the N-terminal 6xHis tag 
upstream to the thrombin cleavage site. MALDI-MS showed the expected molecular weight 




Figure 5.4. The MALDI-MS of wild type CRABP II after thrombin cleavage. 
Figure 5.3. The SDS-PAGE analysis of the 15Bpy-CRABP II purified by Ni affinity 




Figure 5.5. The MALDI-MS of 15Bpy-CRABP II before (top, calc: 17553, exp: 17554) and 
after (bottom, calc: 15790, exp: 15792) thrombin cleavage.  
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The UV-visible spectra of the as purified protein showed a shoulder peak at 350 nm and a 
slope from 400 nm to 650 nm range in addition to the typical 280 nm transition from the protein 
(Figure 5.6). The 350 nm shoulder corresponds to the absorption of the bipyridine motif whereas 









Figure 5.6. The UV-vis spectra as purified 15Bpy-CRABP II. 



















Figure 5.7. The fluorescence spectra of as purified 15Bpy-CRABP II with free bipyridine 
and Fe(bpy)2+ control. 
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the slope in the visible region is likely to be the charge transfer band of Fe(II)-bipyridine. The 
fluorescence emission of the as-purified protein (Figure 5.7) resembles that of pure 
Fe(II)bipyridyl sulfate and is distinct from pure bipyridine ligand which further supports that 
15Bpy-CRABPII was purified with the ferrous ion bound at the active site. 
 The binding affinity of the retinoic acid substrate was measured by fluorometric titration 
as previously reported (Figure 5.8).15 Briefly, the fluoresce of the endogenous tryptophan residue 
is quenched by the substrate retinoic acid at the binding site by proximity based quenching 














































































mechanism, therefore the fluorescence intensity can be used to measure of percentage of 
substrate biding at the binding site. The binding affinity of the 15Bpy-CRABPII is 7.0 nM which 
is comparable to 5.4 nM of the wild type protein, suggesting that protein scaffold was not 
dramatically perturbed. 
 
















 Febpy-CRABP II 
 Febpy-CRABP II
 Febpy-CRABP II
Figure 5.9. The product distribution of EPEA epoxidation catalyzed by 15FeBpy-
CRABP II with H2O2. 
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 The epoxidation of EPEA and DHEA showed very distinct product profile as compared 
to CYP2J2. The CYP2J2 control produces progressively greater percentage of the regioisomer 
towards the hydrophobic terminal of both substrates. However, the artificial enzyme can access 
both the 11,12 and 17,18 C=C double bond in EPEA with comparable yield but have minimal 
activity at the 14,15 position (Figure 5.9). The regioselectivity on the DHEA substrate is 
complementary to that of CYP2J2 (Figure 5.10). The major products are 16,17 and 19,20 
epoxides at the terminal positions whereas 15FeBpy-CRABP II primarily epoxidize the three 
Figure 5.10. The product distribution of DHEA epoxidation catalyzed by 15FeBpy-
CRABP II with H2O2. 
 






















C=C double bonds in the middle namely 7,8-, 10, 11- and 13, 14- positions. 
The artificial enzyme exhibits a certain level of regioselectivity that is distinct from the 
native CYP2J2, however the selectivity is far from ideal. We further hypothesize that the highly 
diffusible H2O2 might promote nonspecific epoxidation at undesired positions, which might be 
prevented by using an oxidant that has a larger molecular weight and less diffusible such as 3-
Chloroperbenzoic acid (mCPBA). The epoxidation of DHEA by mCPBA exhibits a 
regioselectivity that differs from both free ferrous salt and the wild type CRABP II control. 
Interestingly using mCPBA as the oxidant results in the inhibition of the 13,14-epoxidation 
(Figure 5.12). 
























Figure 5.11. The product distribution of EPEA epoxidation catalyzed by 15FeBpy-
CRABP II with mCPBA. 
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The regioselectivity imparted by 15FeBpy-CRABP II can be rationalized by the docking 
simulation of DHA substrate, an analog of DHEA substrate, in the CRABP II scaffold. The DHA 



















Figure 5.12. The product distribution of DHEA epoxidation catalyzed by 15FeBpy-
CRABP II with mCPBA. 
Figure 5.13. The docking simulation of DHA within the cavity of F15W-CRABP II. 
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substrate interacts with the cavity of the -barrel scaffold with the 10,11-olefin closest to the 
designed metal binding site, the second closet positions of 7,8- and 13,14- position, which is 
consistent with the experimentally observed regioselectivity. 
CONCLUSION 
The alternative regioselectivity imparted the artificial metalloenzyme provides a 
complementary product profile to the native enzyme and produces the metabolites of 
polyunsaturated fatty acids which have low abundance in nature. The resultant product can 
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